Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 12:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 387 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hyperlipoproteinemia Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects

NCT02208284
View directory record Official record
Conditions
Healthy
Interventions
PF-06427878, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Not applicable Interventional

The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes

NCT00360217
View directory record Official record
Conditions
Hypertriglyceridemia (TG>200<500), Hyperlipidemia, Coronary Artery Disease, Coronary Risk Equivalent, Diabetes
Interventions
docosahexanoic acid (DHA)
Drug
Lead sponsor
Maine Center for Lipids and Cardiovascular Health
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Scarborough, Maine
Source: ClinicalTrials.gov public record
Updated Nov 18, 2011 · Synced Oct 15, 2026, 12:17 PM EDT
Recruiting No phase listed Observational

HoFH, the International Clinical Collaborators Registry

NCT04815005
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Phase 3 Interventional Results available

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

NCT05952856
View directory record Official record
Conditions
Hypercholesterolemia, Familial Hypercholesterolemia
Interventions
Enlicitide Decanoate, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
49
States / cities
Daphne, Alabama • Foley, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility of an Interval Exercise and Nutrition Intervention to Reduce Cardiovascular Disease Risk Factors

NCT02482922
View directory record Official record
Conditions
Pre-Diabetic, Overweight, Obesity
Interventions
Exercise & Dietary Supplement
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Not applicable Interventional

Controlling Hypertension in Diabetes- Feasibility Study

NCT01145742
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension, Hyperlipidemia
Interventions
home health/primary care collaboration
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
30 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

NCT05563246
View directory record Official record
Conditions
Lipoprotein Disorder
Interventions
LY3473329, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Baltimore, Maryland • Dorchester, Massachusetts • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Phase 3 Interventional Results available

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

NCT05952869
View directory record Official record
Conditions
Hypercholesterolemia, Familial Hypercholesterolemia
Interventions
Enlicitide Decanoate, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Daphne, Alabama • Boca Raton, Florida • Cutler Bay, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Differential Metabolism of Dietary Fatty Acids

NCT00059254
View directory record Official record
Conditions
Obesity, Diabetes, Hyperlipidemia
Interventions
Oleic acid (OA), Palmitic Acid (PA)
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 35 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2005
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects

NCT01806324
View directory record Official record
Conditions
Hypertension, Hyperlipidemia
Interventions
HL040XC, Losartan + Atorvastatin
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
19 Years to 50 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 15, 2026, 12:17 PM EDT
Recruiting Phase 2 Interventional

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial

NCT06488105
View directory record Official record
Conditions
Lipid Disorder, Hypercholesterolemia, Cardiovascular Diseases, Atherosclerosis
Interventions
Statin (rosuvastatin 10 or 40 mg daily, depending on risk), Healthy Lifestyle Counseling, Outpatient Followup
Drug · Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 75 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Phase 3 Interventional Results available

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

NCT03067441
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
bempedoic acid
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Not applicable Interventional

A Pilot Study to Improve Patient-Doctor Communication

NCT01606930
View directory record Official record
Conditions
Chronic Disease, Hypertension, Hyperlipidemia, Diabetes Mellitus, Osteoarthritis, COPD, Cardiovascular Disease
Interventions
Patient Primer Tool
Behavioral
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol

NCT01426412
View directory record Official record
Conditions
Hyperlipidemia
Interventions
LY3015014 IV, Placebo IV, LY3015014 SC, Placebo SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Glendale, California • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 15, 2026, 12:17 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

NCT02651675
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Interventions
AAV directed hLDLR gene therapy
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Boca Raton, Florida • Kansas City, Kansas • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Phase 4 Interventional Results available

Telephone Based Management of Hyperlipidemia

NCT01212159
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Self Monitoring Lipid Analyzer
Device
Lead sponsor
Temple University
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 15, 2026, 12:17 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)

NCT02959762
View directory record Official record
Conditions
Obesity, Insulin Resistance, Obesity in Diabetes, Nutritional and Metabolic Diseases, Hyperlipidemia, Hyperglycemia, Cardiovascular Diseases
Interventions
Placebo-Control, Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Phase 2 Interventional Results available

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

NCT04270760
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Olpasiran, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Beverly Hills, California • Boca Raton, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Not applicable Interventional

HeartBeet Clinic Pilot Trial

NCT06486532
View directory record Official record
Conditions
Hyperlipidemia, Hypertension
Interventions
HeartBeet Clinic, Self-paced education
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 15, 2026, 12:17 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Dietary Sources of Lysophospholipids

NCT02952638
View directory record Official record
Conditions
Obesity, Cardiovascular Risk Factor, Hyperlipidemia
Interventions
Not listed
Lead sponsor
Susan Smyth
Other
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Not applicable Interventional

Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy

NCT00109603
View directory record Official record
Conditions
HIV Infections, Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

NCT03399786
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
evinacumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Boca Raton, Florida • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 15, 2026, 12:17 PM EDT
Completed No phase listed Observational

Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins

NCT00001154
View directory record Official record
Conditions
Hypolipoproteinemia, Hypercholesterolemia, Dyslipidemia, Hyperlipidemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1976
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 12:17 PM EDT
Completed Phase 2 Interventional

A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

NCT01607294
View directory record Official record
Conditions
Hyperlipidemia, Type 2 Diabetes
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 15, 2026, 12:17 PM EDT